Expertise in
15
conditions

Dr. Arvinder S. Bir

Hematology
Ultimate Health Services Inc.
3075 US Route 60, 
Huntington, WV 
Accepting New Patients
Expertise in
15
conditions
Ultimate Health Services Inc.
3075 US Route 60, 
Huntington, WV 

Overview

Arvinder Bir is a Hematologist practicing medicine in Huntington, West Virginia.

Dr. Bir is highly rated in 15 conditions, according to our data. His clinical expertise encompasses Agranulocytosis, Anemia, Large-Cell Immunoblastic Lymphoma, and Muscle Invasive Bladder Cancer.

He is actively involved in clinical research, co-authoring 2 peer reviewed articles and participating in 15 clinical trials. Dr. Bir is currently accepting new patients.

Specialties

Hematology

Licenses

Internal Medicine in WV

Hospital Affiliations

Cabell Huntington Hospital, Inc
St Marys Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
First Health
  • INSURANCE PLAN
  • MEDICARE PDP
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Peak Health
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
The Health Plan
  • HMO
  • MANAGED MEDICAID PLAN
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 12 Less Insurance Carriers -

Locations

Ultimate Health Services Inc.
3075 US Route 60, Huntington, WV 25705

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

15 Clinical Trials

A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
Enrollment Status: Terminated
Publish Date: September 04, 2026
Intervention Type: Other, Drug
Study Drug: Aspirin
Study Phase: Phase 3
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 02, 2026
Intervention Type: Other
Study Phase: Phase 3
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: August 31, 2026
Intervention Type: Radiation, Procedure
Study Phase: Phase 3
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
Enrollment Status: Active_not_recruiting
Publish Date: June 09, 2026
Intervention Type: Other, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 3
A Randomized Phase II/III Trial of Afatinib Plus Cetuximab Versus Afatinib Alone in Treatment-Naive Patients With Advanced, EGFR Mutation Positive Non-small Cell Lung Cancer (NSCLC)
A Randomized Phase II/III Trial of Afatinib Plus Cetuximab Versus Afatinib Alone in Treatment-Naive Patients With Advanced, EGFR Mutation Positive Non-small Cell Lung Cancer (NSCLC)
Enrollment Status: Completed
Publish Date: May 18, 2026
Intervention Type: Drug, Other, Biological
Study Drugs: Afatinib Dimaleate, Cetuximab
Study Phase: Phase 2/Phase 3
A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon With Eflornithine and Sulindac (PACES)
A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon With Eflornithine and Sulindac (PACES)
Enrollment Status: Active_not_recruiting
Publish Date: April 02, 2026
Intervention Type: Drug
Study Phase: Phase 3
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 10, 2026
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Everolimus, Exemestane, Goserelin Acetate, Letrozole, Leuprolide Acetate, Tamoxifen Citrate
Study Phase: Phase 3
A Phase II Study of AMG 510 in Participants With Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN LUNG-MAP SUB-STUDY)
A Phase II Study of AMG 510 in Participants With Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN LUNG-MAP SUB-STUDY)
Enrollment Status: Active_not_recruiting
Publish Date: December 05, 2025
Intervention Type: Drug
Study Drug: Sotorasib
Study Phase: Phase 2
Olanzapine With or Without Fosaprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)in Patients Receiving Highly Emetogenic Chemotherapy (HEC): A Phase III Randomized, Double Blind, Placebo-Controlled Trial
Olanzapine With or Without Fosaprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)in Patients Receiving Highly Emetogenic Chemotherapy (HEC): A Phase III Randomized, Double Blind, Placebo-Controlled Trial
Enrollment Status: Completed
Publish Date: April 06, 2025
Intervention Type: Other, Drug
Study Phase: Phase 3
A Phase II Randomized Study of Ramucirumab Plus MK3475 (Pembrolizumab) Versus Standard of Care for Patients Previously Treated With Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)
A Phase II Randomized Study of Ramucirumab Plus MK3475 (Pembrolizumab) Versus Standard of Care for Patients Previously Treated With Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)
Enrollment Status: Completed
Publish Date: September 03, 2024
Intervention Type: Drug, Biological
Study Drugs: Docetaxel, Gemcitabine, Gemcitabine Hydrochloride, Pembrolizumab, Pemetrexed, Pemetrexed Disodium, Ramucirumab
Study Phase: Phase 2
View 9 Less Clinical Trials

2 Total Publications

Evaluation of Anti-Angiogenic Therapy Combined with Immunotherapy and Chemotherapy as a Strategy to Treat Locally Advanced and Metastatic Non-Small-Cell Lung Cancer.
Evaluation of Anti-Angiogenic Therapy Combined with Immunotherapy and Chemotherapy as a Strategy to Treat Locally Advanced and Metastatic Non-Small-Cell Lung Cancer.
Journal: Cancers
Published: October 31, 2024
Similar Doctors
Expertise in
51
conditions
Dr. Galena Salem
Hematology | Oncology
Expertise in
51
conditions
Dr. Galena Salem
Hematology | Oncology
Referral may be required

Kings Daughters Medcial Specialties Inc

617 23rd St Ste 19, 
Ashland, KY 
 (16.3 miles away)
606-325-2221
Languages Spoken:
English, Russian, Ukrainian
See accepted insurances
Accepting New Patients

Galena Salem is a Hematologist and an Oncologist practicing medicine in Ashland, Kentucky. Dr. Salem is highly rated in 51 conditions, according to our data. Her clinical expertise encompasses Large-Cell Immunoblastic Lymphoma, Non-Hodgkin Lymphoma, Familial Colorectal Cancer, WT1-Related Wilms Tumor Syndromes, and Bone Marrow Transplant. Dr. Salem is currently accepting new patients.

Expertise in
38
conditions
Dr. Vinay Vermani
Hematology | Oncology
Expertise in
38
conditions
Dr. Vinay Vermani
Hematology | Oncology
Referral may be required

Kings Daughters Medcial Specialties Inc

617 23rd St Ste 19, 
Ashland, KY 
 (16.3 miles away)
606-325-2221
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Vinay Vermani is a Hematologist and an Oncologist practicing medicine in Ashland, Kentucky. Dr. Vermani is highly rated in 38 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, Lung Cancer, Pleuropulmonary Blastoma, and Chronic Lymphocytic Leukemia (CLL). Dr. Vermani is currently accepting new patients.

Expertise in
29
conditions
Dr. Chad J. Tarabolous
Hematology | Oncology
Expertise in
29
conditions
Dr. Chad J. Tarabolous
Hematology | Oncology
Referral may be required

Bellefonte Physician Services Inc.

100 Bellefonte Dr, 
Grayson, KY 
 (32.3 miles away)
606-329-9335
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Chad Tarabolous is a Hematologist and an Oncologist practicing medicine in Grayson, Kentucky. Dr. Tarabolous is highly rated in 29 conditions, according to our data. His clinical expertise encompasses Colorectal Cancer, Familial Colorectal Cancer, Lynch Syndrome, and Lung Cancer. Dr. Tarabolous is currently accepting new patients.

Frequently Asked Questions about Dr. Arvinder S. Bir

How do I make an appointment with Dr. Arvinder S. Bir?

You can book an appointment with Dr. Arvinder S. Bir by calling their office at 304-528-4600. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Arvinder S. Bir a top-rated expert for Agranulocytosis?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Arvinder S. Bir is classified as an Distinguished expert for Agranulocytosis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Arvinder S. Bir specialize in?

While Dr. Arvinder S. Bir is a Hematology, they have specific expertise in Agranulocytosis, Anemia, and Large-Cell Immunoblastic Lymphoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Arvinder S. Bir participate in research or clinical trials?

Yes. Dr. Arvinder S. Bir has published 2 articles and abstracts on conditions like Agranulocytosis. You can view a list of Dr. Arvinder S. Bir's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Arvinder S. Bir accept my insurance?

Dr. Arvinder S. Bir accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 304-528-4600 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Bir's expertise for a condition
ConditionClose
    View All 13 Advanced Conditions
    View All 46 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile